CPC C07K 16/28 (2013.01) [A61K 31/5517 (2013.01); A61K 47/6803 (2017.08); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); C07K 16/2866 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/515 (2013.01); C07K 2317/56 (2013.01); C07K 2317/73 (2013.01)] | 6 Claims |
1. A cytotoxic compound represented by the following structural formula:
or a pharmaceutically acceptable salt thereof, wherein:
LD″ and LD′″ are both —H;
LD′ is represented by the following formula:
—NR5—P—C(═O)—(CRaRb)f—Zd1—(CRaRb)r′-JCB (A′)
Zd1 is absent, —C(═O)—NR9— or —NR9—C(═O)—;
P is a peptide containing between 2 to 5 amino acid residues;
Ra and Rb, for each occurrence, are independently —H, (C1-C3)alkyl or a charged substituent or an ionizable group Q;
r and r′ are independently an integer from 1 to 6;
the double line between N and C represents a single bond or a double bond, provided that when it is a double bond X is absent and Y is —H, and when it is a single bond, X is —H, and Y is —OH or —SO3M, wherein M is H+, Na+or K+;
X′ is —H
Y′ is —H
R1, R2, R3, R4, R1′, R2′, R3′ and R4′ are each —H;
R6 is —OMe;
A and A′ are each —O;
R5 and R9 are each independently —H or Me;
JCB is
|